Acro Biomedical Co Stock Net Income
| ACBM Stock | USD 0.02 0.00 0.00% |
As of the 16th of February 2026, ACRO Biomedical shows the Coefficient Of Variation of 812.4, mean deviation of 91.66, and Variance of 142934.45. ACRO Biomedical technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices. Please confirm ACRO Biomedical coefficient of variation, as well as the relationship between the total risk alpha and skewness to decide if ACRO Biomedical is priced adequately, providing market reflects its regular price of 0.0222 per share. As ACRO Biomedical appears to be a penny stock we also recommend to validate its information ratio numbers.
ACRO Biomedical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ACRO Biomedical's valuation are provided below:ACRO Biomedical Co does not right now have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. ACRO |
ACRO Biomedical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ACRO Biomedical's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ACRO Biomedical.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in ACRO Biomedical on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding ACRO Biomedical Co or generate 0.0% return on investment in ACRO Biomedical over 90 days. Acro Biomedical Co., Ltd. engages in developing and marketing of nutritional products More
ACRO Biomedical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ACRO Biomedical's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ACRO Biomedical Co upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1229 | |||
| Maximum Drawdown | 3071.43 |
ACRO Biomedical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ACRO Biomedical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ACRO Biomedical's standard deviation. In reality, there are many statistical measures that can use ACRO Biomedical historical prices to predict the future ACRO Biomedical's volatility.| Risk Adjusted Performance | 0.1093 | |||
| Jensen Alpha | 47.01 | |||
| Total Risk Alpha | 18.44 | |||
| Treynor Ratio | (5.76) |
ACRO Biomedical February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1093 | |||
| Market Risk Adjusted Performance | (5.75) | |||
| Mean Deviation | 91.66 | |||
| Coefficient Of Variation | 812.4 | |||
| Standard Deviation | 378.07 | |||
| Variance | 142934.45 | |||
| Information Ratio | 0.1229 | |||
| Jensen Alpha | 47.01 | |||
| Total Risk Alpha | 18.44 | |||
| Treynor Ratio | (5.76) | |||
| Maximum Drawdown | 3071.43 | |||
| Skewness | 8.12 | |||
| Kurtosis | 66.0 |
ACRO Biomedical Backtested Returns
ACRO Biomedical is out of control given 3 months investment horizon. ACRO Biomedical secures Sharpe Ratio (or Efficiency) of 0.13, which signifies that the company had a 0.13 % return per unit of risk over the last 3 months. We have analyzed sixteen different technical indicators, which can help you to evaluate if expected returns of 15.63% are justified by taking the suggested risk. Use ACRO Biomedical Coefficient Of Variation of 812.4, mean deviation of 91.66, and Variance of 142934.45 to evaluate company specific risk that cannot be diversified away. ACRO Biomedical holds a performance score of 9 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -8.08, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning ACRO Biomedical are expected to decrease by larger amounts. On the other hand, during market turmoil, ACRO Biomedical is expected to outperform it. Use ACRO Biomedical information ratio, skewness, as well as the relationship between the Skewness and day median price , to analyze future returns on ACRO Biomedical.
Auto-correlation | 0.00 |
No correlation between past and present
ACRO Biomedical Co has no correlation between past and present. Overlapping area represents the amount of predictability between ACRO Biomedical time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ACRO Biomedical price movement. The serial correlation of 0.0 indicates that just 0.0% of current ACRO Biomedical price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, ACRO Biomedical Co reported net income of 7.7 M. This is 97.74% lower than that of the Healthcare sector and 89.01% lower than that of the Biotechnology industry. The net income for all United States stocks is 98.65% higher than that of the company.
ACRO Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ACRO Biomedical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of ACRO Biomedical could also be used in its relative valuation, which is a method of valuing ACRO Biomedical by comparing valuation metrics of similar companies.ACRO Biomedical is currently under evaluation in net income category among its peers.
ACRO Fundamentals
| Return On Equity | -29.78 | |||
| Return On Asset | -15.5 | |||
| Operating Margin | (17.61) % | |||
| Current Valuation | 240.18 M | |||
| Shares Outstanding | 60.04 M | |||
| Shares Owned By Insiders | 49.97 % | |||
| Price To Book | 487.98 X | |||
| Price To Sales | 267.90 X | |||
| Revenue | 1.2 M | |||
| Gross Profit | 259.5 K | |||
| EBITDA | (7.69 M) | |||
| Net Income | 7.7 M | |||
| Cash And Equivalents | 12.11 K | |||
| Total Debt | 59.44 K | |||
| Debt To Equity | 0.10 % | |||
| Current Ratio | 7.70 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | 299.33 K | |||
| Earnings Per Share | (0.20) X | |||
| Beta | 0.92 | |||
| Market Capitalization | 209.55 M | |||
| Total Asset | 761.08 K | |||
| Net Asset | 761.08 K |
About ACRO Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ACRO Biomedical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ACRO Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ACRO Biomedical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in ACRO Pink Sheet
ACRO Biomedical financial ratios help investors to determine whether ACRO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ACRO with respect to the benefits of owning ACRO Biomedical security.